/
Cardiovascular
Heart Failure
151
Pipeline Programs↗
419
Active Trials↗
137
Companies Involved↗
Heart Failure is a highly competitive landscape with 151 programs across 137 companies. The most active players are Novo Nordisk, Bristol-Myers Squibb, Otsuka. 25 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical92
Phase 111
Phase 223
Phase 325
Approved
No programs
Analysis
Modality Breakdown
96%
Small molecule
133 of 138 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 138 classified programs, each share of the total. Modality classified for 96% of 151 pipeline programs.
Analysis
Trial Status
1,450
clinical trials
Completed665 · 46%
Recruiting225 · 16%
Unknown status165 · 11%
Terminated130 · 9%
Not yet recruiting101 · 7%
Active, not recruiting71 · 5%
Other93 · 6%
Clinical Trials
Trial Activity
1450 trials
Page 1 of 97
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)